title: The effects of R-salbutamol on growth, carcass measures, and health of finishing pigs.
abstract: A pure form of salbutamol has the potential to deliver positive production benefits to the swine industry. The aim of this experiment was to determine the effects of salbutamol on growth, carcass measures, and health of finishing pigs. The study used 192 pigs (89 ± 1 kg BW) housed in groups of 6 in 32 pens and assigned to 1 of 4 treatments: 1) control (CTL), 0 mg/kg salbutamol; 2) 2R, control diet with 2 mg/kg of the pure R-enantiomer of salbutamol; 3) 4R, control diet with 4 mg/kg of pure R-salbutamol; or 4) 8RS, control diet with 8 mg/kg of a 50:50 mixture of the R- and S-enantiomers. All diets were offered ad libitum for 4 wk. All pigs were weighed and pen feed intakes were recorded weekly. At slaughter, individual HCW and measurements of the 10th-rib loin muscle area (LMA), color, marbling, firmness, and back fat, last lumbar, and midline back fat depths were collected. Data were analyzed using Proc GLM of SAS, with pen as the experimental unit. Overall, 2R and 4R pigs had greater ADG than CTL pigs (P < 0.05) and, at slaughter, were heavier than CTL pigs (P < 0.01). Overall, 8RS pigs had decreased ADFI (P < 0.05), and CTL pigs had poorer G:F (P < 0.001) than the other 3 treatments. All salbutamol-fed pigs had 5 to 6 kg greater HCW (P < 0.001), 2% to 3% increased carcass yield (P < 0.001), 5.6 cm(2) larger LMA (P < 0.01), 3 to 4 mm less 10th-rib back fat (P < 0.01), and 2 mm less lumbar back fat (P < 0.05) than CTL pigs. However, control pigs had greater loin muscle color scores (P < 0.05) and marbling scores (P < 0.001) than all salbutamol-treated pigs. Taken together, these data indicate that as little as 2 mg/kg R-salbutamol has a positive effect on pig growth and carcass composition. However, the effects of salbutamol on meat quality require further research.
authors.affiliation: ARS-USDA, Livestock Behavior Research Unit, Purdue University, West Lafayette, IN 47907, USA. jeremy.marchant-forde@ars.usda.gov
authors.forename: J N
authors.initials: JN
authors.lastname: Marchant-Forde
authors.forename: D C
authors.initials: DC
authors.lastname: Lay
authors.forename: R M
authors.initials: RM
authors.lastname: Marchant-Forde
authors.forename: K A
authors.initials: KA
authors.lastname: McMunn
authors.forename: B T
authors.initials: BT
authors.lastname: Richert
mesh_terms: D058666:Adrenergic beta-2 Receptor Agonists / Q000494:pharmacology*; D000420:Albuterol / Q000494:pharmacology*; D000818:Animals; D001823:Body Composition / Q000187:drug effects* / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D005260:Female; D008297:Male; D013552:Swine / Q000254:growth & development* / Q000502:physiology; D015430:Weight Gain / Q000187:drug effects
chemical_list: D058666:Adrenergic beta-2 Receptor Agonists; D000420:Albuterol